134 related articles for article (PubMed ID: 37279797)
1. A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Atkins SLP; Greer YE; Jenkins S; Gatti-Mays ME; Houston N; Lee S; Lee MJ; Rastogi S; Sato N; Burks C; Annunziata CM; Lee JM; Nagashima K; Trepel JB; Lipkowitz S; Zimmer AS
Oncologist; 2023 Oct; 28(10):919-e972. PubMed ID: 37279797
[TBL] [Abstract][Full Text] [Related]
2. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
3. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
Stein MN; Malhotra J; Tarapore RS; Malhotra U; Silk AW; Chan N; Rodriguez L; Aisner J; Aiken RD; Mayer T; Haffty BG; Newman JH; Aspromonte SM; Bommareddy PK; Estupinian R; Chesson CB; Sadimin ET; Li S; Medina DJ; Saunders T; Frankel M; Kareddula A; Damare S; Wesolowsky E; Gabel C; El-Deiry WS; Prabhu VV; Allen JE; Stogniew M; Oster W; Bertino JR; Libutti SK; Mehnert JM; Zloza A
J Immunother Cancer; 2019 May; 7(1):136. PubMed ID: 31118108
[TBL] [Abstract][Full Text] [Related]
4. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.
Yuan X; Kho D; Xu J; Gajan A; Wu K; Wu GS
Oncotarget; 2017 Mar; 8(13):21626-21638. PubMed ID: 28423492
[TBL] [Abstract][Full Text] [Related]
5. First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.
Stein MN; Bertino JR; Kaufman HL; Mayer T; Moss R; Silk A; Chan N; Malhotra J; Rodriguez L; Aisner J; Aiken RD; Haffty BG; DiPaola RS; Saunders T; Zloza A; Damare S; Beckett Y; Yu B; Najmi S; Gabel C; Dickerson S; Zheng L; El-Deiry WS; Allen JE; Stogniew M; Oster W; Mehnert JM
Clin Cancer Res; 2017 Aug; 23(15):4163-4169. PubMed ID: 28331050
[No Abstract] [Full Text] [Related]
6. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
[TBL] [Abstract][Full Text] [Related]
8. Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.
Pierce SR; Fang Z; Yin Y; West L; Asher M; Hao T; Zhang X; Tucker K; Staley A; Fan Y; Sun W; Moore DT; Xu C; Tsai YH; Parker J; Prabhu VV; Allen JE; Lee D; Zhou C; Bae-Jump V
J Exp Clin Cancer Res; 2021 Feb; 40(1):61. PubMed ID: 33557912
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS; Nichols E; Cimino-Mathews A; Peer C; Cao L; Lee MJ; Kohn EC; Annunziata CM; Lipkowitz S; Trepel JB; Sharma R; Mikkilineni L; Gatti-Mays M; Figg WD; Houston ND; Lee JM
J Immunother Cancer; 2019 Jul; 7(1):197. PubMed ID: 31345267
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Matulonis U; Vergote I; Backes F; Martin LP; McMeekin S; Birrer M; Campana F; Xu Y; Egile C; Ghamande S
Gynecol Oncol; 2015 Feb; 136(2):246-53. PubMed ID: 25528496
[TBL] [Abstract][Full Text] [Related]
11. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
12. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U; van Herpen CML; Saura C; Thistlethwaite F; Lord S; Moreno V; Macpherson IR; Boni V; Rolfo C; de Vries EGE; Rottey S; Geenen J; Eskens F; Gil-Martin M; Mommers EC; Koper NP; Aftimos P
Lancet Oncol; 2019 Aug; 20(8):1124-1135. PubMed ID: 31257177
[TBL] [Abstract][Full Text] [Related]
14. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Heudel PE; Fabbro M; Roemer-Becuwe C; Kaminsky MC; Arnaud A; Joly F; Roche-Forestier S; Meunier J; Foa C; You B; Priou F; Tazi Y; Floquet A; Selle F; Berton-Rigaud D; Lesoin A; Kalbacher E; Lortholary A; Favier L; Treilleux I; Ray-Coquard I
Br J Cancer; 2017 Jan; 116(3):303-309. PubMed ID: 28072765
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K
Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491
[TBL] [Abstract][Full Text] [Related]
17. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
[TBL] [Abstract][Full Text] [Related]
19. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
Talekar MK; Allen JE; Dicker DT; El-Deiry WS
Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
